Genmab A/S Receives Patent For HuMax-HepC
COPENHAGEN, Denmark, Nov. 3 /PRNewswire-FirstCall/ -- Genmab A/S (CSE: GEN) announced today that a patent has been issued for HuMax(R)-HepC by the US Patent and Trademark Office. HuMax-HepC is a fully human antibody currently in pre-clinical development to prevent reinfection with the Hepatitis C Virus (HCV) after liver transplantation. HuMax-HepC binds to a common site on diverse strains of the virus. In pre-clinical studies, the antibody prevented the HCV from attaching to susceptible cells.
"The issuance of the HuMax-HepC patent marks another important milestone in building our business," said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab. "The patent provides broad protection over this unique antibody and gives us a potential edge over other biotech companies competing in the same arena."
About Genmab A/S
Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. At present, Genmab has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche, Amgen and Serono. A broad alliance provides Genmab with access to Medarex, Inc.'s array of proprietary technologies, including the UltiMAb(R) platform for the rapid creation and development of human antibodies to virtually any disease target. Genmab has operations in Copenhagen, Denmark, Utrecht, the Netherlands, and Princeton, New Jersey in the US. For more information about Genmab, visit http://www.genmab.com.
This press release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with product discovery and development, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. Genmab is not under an obligation to up-date statements regarding the future following the publication of this release; nor to confirm such statements in relation to actual results, unless this is required by law.
UltiMAb(R) is a trademark of Medarex, Inc.
Genmab(R); HuMax(R); HuMax-CD4(TM) and the Y-shaped Genmab logo are all trademarks of Genmab A/S.Genmab A/S
CONTACT: Helle Husted, Director, Investor Relations of Genmab,+45-33-44-77-30, Cell: +45-25-27-47-13, firstname.lastname@example.org
Web site: http://www.genmab.com/